Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20150630022991N10
IRCT20150630022991N10
Recruiting
Phase 2

Comparison of the Efficacy of Escitalopram, Venlafaxine and Buspirone on the Symptoms and Quality of Life in Irritable Bowel Syndrome Patients

Babol University of Medical Sciences0 sites90 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIrritable bowel syndrome.Irritable bowel syndrome

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Irritable bowel syndrome.
Sponsor
Babol University of Medical Sciences
Enrollment
90
Status
Recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •The Presence of ROME\-III Diagnostic Criteria for Diagnosis of Irritable Bowel Syndrome
  • •To Provide the Informed Consent Form of the Patient for Participation in the Study

Exclusion Criteria

  • •Age under 18 years
  • •Allergy to Escitalopram, Venlafaxine or Buspirone
  • •The presence of warning signs such as chronic fever, weight loss, gastrointestinal bleeding
  • •Pregnancy and breast feeding
  • •Use of any drug that can affect the bowel function (such as laxatives, anti\-diarrhea, antibiotics and probiotics) within one month before entering the study
  • •Known cases of lactose intolerance
  • •Severe physical illnesses, mental retardation, dementia, psychosis, and the existence of serious suicidal ideation and substance dependence that affects patients' compliance with the study protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Treatment of depressive symptoms in patients with heart failureDepression.Major depressive disorder, single episode, mildF32.0
IRCT20190525043700N5Babol University of Medical Sciences80
Not yet recruiting
Not Applicable
Effect of antidepressant drug desvenlafaxine on anxiety and plasma BDNF level in patients.Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
CTRI/2021/11/038260Dr Chaitali Chindhalore
Completed
Phase 2
Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticismeuroticism or neuroticism.Post-traumatic stress disorder, acuteF43.11
IRCT20211208053331N1Ahvaz University of Medical Sciences172
Completed
Phase 4
Comparison Of Two Anti Depressant Drugs In Major Depressive DisorderHealth Condition 1: null- Major Depressive Disorder
CTRI/2018/02/011662Government Medical College50
Completed
Not Applicable
Efficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trialmajor depressive disorder
JPRN-UMIN000011191Department of Psychiatry, Fujita Health University School of Medicine200